Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada

Detalles Bibliográficos
Autores principales: Gerth, William C, Betschel, Stephen D, Zbrozek, Arthur S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125998/
http://dx.doi.org/10.1186/1710-1492-10-S1-A42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125998/
http://dx.doi.org/10.1186/1710-1492-10-S1-A42

Ejemplares similares